sb 203580 has been researched along with nicorandil in 2 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (nicorandil) | Trials (nicorandil) | Recent Studies (post-2010) (nicorandil) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 1,487 | 207 | 428 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aggeli, IK; Beis, I; Gaitanaki, C; Iliodromitis, EK; Kremastinos, DT; Tsiafoutis, I; Zoga, A | 1 |
Li, J; Wang, H; Xiao, Y; Xie, W; Yu, Y; Zuo, X | 1 |
2 other study(ies) available for sb 203580 and nicorandil
Article | Year |
---|---|
p38-MAPK is involved in restoration of the lost protection of preconditioning by nicorandil in vivo.
Topics: Animals; Anti-Arrhythmia Agents; Cyclic GMP; Imidazoles; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Nicorandil; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Potassium Channels; Protein Kinase C; Pyridines; Rabbits; Signal Transduction | 2008 |
Protective effect of nicorandil on hypoxia‑induced apoptosis in HPAECs through inhibition of p38 MAPK phosphorylation.
Topics: Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspase 8; Caspase 9; Cell Hypoxia; Cells, Cultured; Endothelial Cells; Humans; Imidazoles; Nicorandil; Nitric Oxide Synthase Type III; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Vasodilator Agents | 2013 |